Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference

详细信息    查看全文

• 作者：Niklas Thon ; Jun Thorsteinsdottir ; Sabina Eigenbrod…
• 关键词：Glioblastoma ; MGMT ; Biopsy ; Extent of resection ; Outcome ; Prognostic factors
• 刊名：Journal of Neurology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：264
• 期：2
• 页码：350-358
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Neurology; Neurosciences; Neuroradiology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-1459
• 卷排序：264

文摘

In 2011, we reported a predominant prognostic/predictive role of MGMT promoter methylation status on progression-free survival (PFS) in unresectable glioblastoma patients undergoing upfront radiotherapy plus concomitant and maintenance temozolomide (RTX/TMZ → TMZ). We, here, present the final results of this prospective study focussing on the prognostic/predictive value of MGMT promoter methylation status for death risk stratification. Overall, 56 adult patients with unresectable, biopsy proven glioblastoma were prospectively assigned to upfront RTX/TMZ → TMZ treatment between March 2006 and August 2008. Last follow-up was performed in June 2016. MGMT promoter methylation was determined using methylation-specific PCR (MSP) and sodium bisulfite sequencing. Analyses were done by intention to treat. Prognostic factors were obtained from proportional hazard models. At the time of the final analysis 55 patients showed progressive disease and 53 patients had died. MGMT promoter was methylated (unmethylated) in 30 (26) patients. Methylation of the MGMT promoter was the strongest favorable predictor for overall survival (OS, median: 20.3 vs. 7.3 months, p < 0.001, HR 0.30, 95% CI 0.16–0.55), and PFS (median: 15.0 vs. 6.1 months, p < 0.001, HR 0.31, 95% CI 0.17–0.57) and was also associated with higher frequencies of treatment response and prolonged post-recurrence survival (PRS, median: 4.5 vs. 1.4 months, p < 0.002, HR 0.39, 95% CI 0.21–0.71). Knowledge of MGMT promoter methylation status is essential for patients’ counseling, prognostic evaluation, and for the design of future trials dealing with unresectable glioblastomas.